Cormorant Asset Management: Comparing Q3 and Q4 2022 Holdings of Top Stocks

Cormorant Asset Management, LP - a global investment management company - recently released their Q4 2022 13F holdings report, revealing the top stocks held by the firm during the final quarter of the year. To get a better understanding of their performance, we compared their Q4 2022 holdings with their Q3 2022 holdings for the top stocks, as summarized in this article.

The comparison reveals that Cormorant Asset Management, LP increased their holdings in some stocks, reduced their stake in some stocks, and even added new stocks to their portfolio during the quarter. Continue reading to find out more about these stocks and changes in shareholdings.

Prometheus Biosciences Inc (RXDX)

Cormorant Asset Management LP increased its shares in Prometheus Biosciences by 5.6%, from 1,979,158 in Q3 to 2,090,000 in Q4. The value of the shares also increased significantly from $116,790 to $229,900, a change of 96.8%, reflecting their confidence in the company's performance.

Apellis Pharmaceuticals Inc (APLS)

Cormorant Asset Management LP reduced its shares in Apellis Pharmaceuticals by 6.6%, from 1,478,000 in Q3 to 1,576,872 in Q4. The value of the shares also decreased significantly from $100,947 to $81,540, a drop of 19.2%.

Arcellx Inc (ACLX)

Cormorant Asset Management LP reduced its shares in Arcellx by 32.1%, from 3,049,173 in Q3 to 2,075,000 in Q4. However, the value of the shares increased slightly from $57,233 to $64,284, a change of 12.3%.

MoonLake Immunotherapeutics (MLTX)

Cormorant Asset Management LP maintained its shares in MoonLake Immunotherapeutics at 6,065,001 in both Q3 and Q4. However, the value of the shares increased significantly from $47,064 to $63,683, a change of 35.3%.

Avidity Biosciences Inc (RNA)

Cormorant Asset Management LP increased its shares in Avidity Biosciences by 37.3%, from 2,012,115 in Q3 to 2,762,115 in Q4. The value of the shares also increased significantly from $32,858 to $61,291, a change of 86.5%.

Design Therapeutics Inc (DSGN)

Cormorant Asset Management LP increased its shares in Design Therapeutics by 3%, from 5,000,000 in Q3 to 5,150,000 in Q4. However, the value of the shares decreased significantly from $83,600 to $52,839, a drop of 36.8%.

Erasca Inc (ERAS)

Cormorant Asset Management LP increased its shares in Erasca by 2.9%, from 10,505,554 in Q3 to 10,813,246 in Q4. However, the value of the shares decreased significantly from $81,943 to $46,605, a drop of 43.1%.

Revolution Medicines Inc (RVMD)

Cormorant Asset Management LP reduced its shares in Revolution Medicines by 5%, from 1,995,066 in Q3 to 1,895,066 in Q4. However, the value of the shares increased slightly from $39,343 to $45,140, a change of 14.7%.

AltimMune Inc (ALT)

Cormorant Asset Management LP reduced its shares in AltimMune by 24.5%, from 3,442,863 in Q3 to 2,600,000 in Q4. The value of the shares also decreased slightly from $43,965 to $42,770, a drop of 2.7%.

Centessa Pharmaceuticals PLC (CMTA)

Cormorant Asset Management LP reduced its shares in Centessa Pharmaceuticals significantly by 71.9%, from 1,972,728 in Q3 to 561,600 in Q4. The value of the shares also decreased significantly from $79,330 to $17,411, a drop of 78%.

Conclusion

Overall, Cormorant Asset Management’s Q4 2022 13F holdings report revealed some interesting changes in their portfolio in terms of stock investments. While they increased their shares in some companies, reduced shares in others, and even added new positions to their portfolio, they remained active investors in the life sciences and healthcare sectors. As with any investment, there is no guarantee of returns, but these changes in holdings could give investors insights into Cormorant's strategy in the coming months.